3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
23
Gastrointestinal
7
CNS
3
Plasma cell
2
Lymphoid
2
Head & Neck
2
Gynecologic
2
Genitourinary
2
Tumor-Agnostic
1
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Dermatologic
1
Conditions
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Breast Neoplasms
1
Interventions
Specimen Handling
27
Magnetic Resonance Spectroscopy
23
Cyclophosphamide
16
Biopsy
15
Doxorubicin
14
pembrolizumab
12
X-Rays
12
Radiation
12
Radiotherapy
10
Temozolomide
9
Phantoms, Imaging
9
Vincristine
7
Irinotecan
7
Nivolumab
6
Ifosfamide
6
atezolizumab
5
Gemcitabine
5
palbociclib
4
liposomal doxorubicin
4
fludarabine
4
cemiplimab
4
cabozantinib
4
Immunoglobulin G
4
Imatinib Mesylate
4
Etoposide
4
Dactinomycin
4
Carboplatin
4
Bevacizumab
4
selinexor
3
olaparib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Trastuzumab
×
Sarcoma
×
30 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled